EDIT - エディタス・メディシン (Editas Medicine Inc.) エディタス・メディシン

 EDITのチャート


 EDITの企業情報

symbol EDIT
会社名 Editas Medicine Inc (エディタス・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エディタス・メディシン(Editas Medicine Inc.)はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復(CRISPR)技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9(Cas9)またはPrevotellaおよびFrancisella 1(Cpf1)由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸(RNA)複合体を使用し、特定のデオキシリボ核酸(DNA)配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10(LCA10)のゲノム編集治療薬を開発している。   エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子ゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。  Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
本社所在地 11 Hurley Street Cambridge MA 02141 USA
代表者氏名 James C. Mullen ジェームスC.ミューレン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9000
設立年月日 41518
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 112人
url www.editasmedicine.com
nasdaq_url https://www.nasdaq.com/symbol/edit
adr_tso
EBITDA EBITDA(百万ドル) -131.47100
終値(lastsale) 27.88
時価総額(marketcap) 1329196954.72
時価総額 時価総額(百万ドル) 1323.476
売上高 売上高(百万ドル) 21.24800
企業価値(EV) 企業価値(EV)(百万ドル) 112.34
当期純利益 当期純利益(百万ドル) -132.45000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense).

 EDITのテクニカル分析


 EDITのニュース

   Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y  2020/05/08 11:38:00 Zacks Investment Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
   Modalis Obtains Access to Foundational CRISPR IP  2020/04/01 04:00:00 Business Wire
TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #CRISPR--Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine. Modalis is utilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional details inc
   Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?  2020/03/27 15:31:01 Zacks Investment Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Editas, Allergan Start Dosing in Early-Stage Eye Disease Study  2020/03/05 13:29:00 Zacks Investment Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
   Editas' (EDIT) Earnings Beat in Q1, Revenues Improve Y/Y  2020/05/08 11:38:00 Zacks Investment Research
Editas (EDIT) beats on earnings in the first quarter of 2020 while revenues slightly miss estimates.
   Modalis Obtains Access to Foundational CRISPR IP  2020/04/01 04:00:00 Business Wire
TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #CRISPR--Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine. Modalis is utilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional details inc
   Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?  2020/03/27 15:31:01 Zacks Investment Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Editas, Allergan Start Dosing in Early-Stage Eye Disease Study  2020/03/05 13:29:00 Zacks Investment Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
   Modalis Obtains Access to Foundational CRISPR IP  2020/04/01 04:00:00 Business Wire
TOKYO & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #CRISPR--Modalis Therapeutics Corporation (Modalis) today announced that the company has entered into a license agreement with Editas Medicine, Inc., under which Modalis has obtained a license to certain intellectual property that is controlled by Editas Medicine. Modalis is utilizing its proprietary epigenetic gene modulation technology, CRISPR-GNDM (Guide Nucleotide Directed Modulation), to treat patients with serious genetic disorders. Additional details inc
   Editas (EDIT) Up 0.1% Since Last Earnings Report: Can It Continue?  2020/03/27 15:31:01 Zacks Investment Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
   The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings  2020/03/13 11:52:53 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo Corporation (NASDAQ: MASI ) Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) Abbott Laboratories (NYSE: ABT ) ABIOMED, Inc. (NASDAQ: ABMD ) Acasti Pharma Inc (NASDAQ: ACST ) Accelerate Diagnostics Inc (NASDAQ: AXDX ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Achieve Life Sciences Inc (NASDAQ: ACHV ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Adamas Pharmaceuticals Inc (NASDAQ: ADMS ) Adamis Pharmaceuticals Corp (NASDAQ: ADM ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) ADDEX THERAPEUT/ADR (NASDAQ: ADXN ) ADMA Biologics Inc (NASDAQ: ADMA ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Aerie Pharmaceuticals Inc (NASDAQ: AERI ) AEterna Zentaris Inc. (NASDAQ: AEZS ) Affimed NV (NASDAQ: AFMD ) Aileron Therapeutics Inc (NASDAQ: ALRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Akari Therapeutics PLC (NASDAQ: AKTX ) Akcea Therapeutics Inc (NASDAQ: AKCA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Akers Biosciences Inc (NASDAQ: AKER ) Akorn, Inc.
   Editas, Allergan Start Dosing in Early-Stage Eye Disease Study  2020/03/05 13:29:00 Zacks Investment Research
Editas (EDIT) and Allergan are co-developing a CRISPR-based candidate, AGN-151587, for treating Leber congenital amaurosis 10 (LCA10), an inherited form of blindness.
   Editas (EDIT) Q4 Earnings & Sales Fall Shy of Estimates  2020/02/27 19:56:00 Zacks Investment Research
Editas (EDIT) misses on earnings and revenues in fourth-quarter 2019.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エディタス・メディシン EDIT Editas Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)